Regarding "recommendations for zoledronic acid treatment of patients with bone metastases".
Parles
Karen
K
D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004502:Education, Medical, Continuing / Q000592:standards*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D017410:Practice Guidelines as Topic; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D003404:Creatinine